Cargando…

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies

Since the first COVID-19 reports back in December of 2019, this viral infection caused by SARS-CoV-2 has claimed millions of lives. To control the COVID-19 pandemic, the Food and Drug Administration (FDA) and/or European Agency of Medicines (EMA) have granted Emergency Use Authorization (EUA) to nin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almagro, Juan C., Mellado-Sánchez, Gabriela, Pedraza-Escalona, Martha, Pérez-Tapia, Sonia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456190/ https://www.ncbi.nlm.nih.gov/pubmed/36077159 http://dx.doi.org/10.3390/ijms23179763

Ejemplares similares

Phage Display Libraries for Antibody Therapeutic Discovery and Development
por: Almagro, Juan C., et al.
Publicado: (2019)

Anti-SARS-CoV-2 Omicron Antibodies Isolated from a SARS-CoV-2 Delta Semi-Immune Phage Display Library
por: Mendoza-Salazar, Ivette, et al.
Publicado: (2022)

Efficacy, Pharmacokinetics, and Toxicity Profiles of a Broad Anti-SARS-CoV-2 Neutralizing Antibody
por: Godínez-Palma, Silvia, et al.
Publicado: (2023)

Discovery and Optimization of Neutralizing SARS-CoV-2 Antibodies Using ALTHEA Gold Plus Libraries™
por: Guzmán-Bringas, Omar U., et al.
Publicado: (2023)

In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a Semi-Immune Phage Display Library
por: González-González, Edith, et al.
Publicado: (2022)

ALTHEA Gold Libraries™: antibody libraries for therapeutic antibody discovery
por: Valadon, Philippe, et al.
Publicado: (2019)

Performance of Elecsys Anti-SARS CoV-2 (Roche) and VIDAS Anti-SARS CoV-2 (Biomérieux) for SARS-CoV-2 Nucleocapsid and Spike Protein Antibody Detection
por: Inés, Riberi María, et al.
Publicado: (2022)

SARS-CoV-2 and Anti-Cardiolipin Antibodies
por: Jizzini, Mazen, et al.
Publicado: (2020)

Impact of therapeutic plasma exchange on acquired vaccinal anti-SARS-CoV-2 antibodies
por: Lambert, Catherine, et al.
Publicado: (2022)

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
por: Cho, Alice, et al.
Publicado: (2021)

Therapeutic antibodies under development for SARS‐CoV‐2
por: Ma, Zetong, et al.
Publicado: (2021)

Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™
por: Pedraza-Escalona, M., et al.
Publicado: (2021)

Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2
por: Huang, Kuan-Ying A., et al.
Publicado: (2022)

Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics
por: House, Robert V., et al.
Publicado: (2022)

Automated ELISA On-Chip for the Detection of Anti-SARS-CoV-2 Antibodies
por: González-González, Everardo, et al.
Publicado: (2021)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

Evolution of antibody profiles against SARS-CoV-2 in experienced and naïve vaccinated elderly people
por: Sanz-Muñoz, Iván, et al.
Publicado: (2023)

Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease
por: Martin-Arranz, M. D., et al.
Publicado: (2023)

Absence of SARS‐CoV‐2 RNA and anti‐SARS‐CoV‐2 antibodies in stray cats
por: Stranieri, Angelica, et al.
Publicado: (2021)

SARS-CoV-2 infection associated with diplopia and anti-acetylcholine receptor antibodies()
por: Pérez Álvarez, Á.I., et al.
Publicado: (2020)

Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
por: Almagro, Juan C., et al.
Publicado: (2018)

Longitudinal anti-SARS-CoV-2 antibody immune response in acute and convalescent patients
por: Pérez-Juárez, Horacio, et al.
Publicado: (2023)

Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery
por: Torres-Pérez, Sergio Andrés, et al.
Publicado: (2020)

Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization
por: Klasse, PJ, et al.
Publicado: (2020)

SARS-CoV-2 spike therapeutic antibodies in the age of variants
por: Baum, Alina, et al.
Publicado: (2021)

Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics
por: Focosi, Daniele, et al.
Publicado: (2022)

Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies
por: Li, Ruofan, et al.
Publicado: (2022)

Long-Term Persistence of Anti-SARS-CoV-2 Antibodies in a Pediatric Population
por: Méndez-Echevarría, Ana, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Nazemipour, Maryam, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Ghafari, Mahan, et al.
Publicado: (2021)

Immunoassays for anti-SARS-CoV-2 antibodies: recent insights
por: Van Elslande, Jan, et al.
Publicado: (2021)

Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies
por: Xue, Jun-biao, et al.
Publicado: (2021)

SARS-CoV-2 infection in patients with chronic kidney disease on haemodialysis. Evolution of SARS-CoV-2 CRP()
por: Zúñiga, José, et al.
Publicado: (2021)

Seroprevalence of anti-SARS-CoV-2 antibodies in Colombia, 2020: A population-based study
por: Mercado-Reyes, Marcela, et al.
Publicado: (2022)

Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance
por: Perez-Saez, Javier, et al.
Publicado: (2021)

Competitive Immunoassay of SARS-CoV-2 Using Pig Sera-Derived Anti-SARS-CoV-2 Antibodies
por: Bong, Ji-Hong, et al.
Publicado: (2021)

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants
por: Makdasi, Efi, et al.
Publicado: (2021)

Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!
por: Mveang Nzoghe, Amandine, et al.
Publicado: (2021)

Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak
por: Stringhini, Silvia, et al.
Publicado: (2021)

Neutralizing antibodies for SARS-CoV-2 infection
por: Berenguer, Juan
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mp1m8ood05rqp6m49fq809itne